Italy
· Delayed Price · Currency is EUR Ulisse Biomed Statistics
Total Valuation
Ulisse Biomed has a market cap or net worth of EUR 20.42 million. The enterprise value is 19.25 million.
| Market Cap | 20.42M |
| Enterprise Value | 19.25M |
Important Dates
The next estimated earnings date is Friday, June 27, 2025.
| Earnings Date | Jun 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Ulisse Biomed has 24.48 million shares outstanding.
| Current Share Class | 24.48M |
| Shares Outstanding | 24.48M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.59 |
| PB Ratio | 0.86 |
| P/TBV Ratio | 4.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.24 |
| EV / Sales | 25.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.40 |
Financial Position
The company has a current ratio of 2.44, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.44 |
| Quick Ratio | 1.60 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.09 |
| Interest Coverage | -255.42 |
Financial Efficiency
Return on equity (ROE) is -23.28% and return on invested capital (ROIC) is -14.93%.
| Return on Equity (ROE) | -23.28% |
| Return on Assets (ROA) | -13.05% |
| Return on Invested Capital (ROIC) | -14.93% |
| Return on Capital Employed (ROCE) | -24.64% |
| Revenue Per Employee | 95,991 |
| Profits Per Employee | -742,477 |
| Employee Count | 10 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 0.98 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.72% in the last 52 weeks. The beta is 0.71, so Ulisse Biomed's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | -28.72% |
| 50-Day Moving Average | 0.78 |
| 200-Day Moving Average | 0.86 |
| Relative Strength Index (RSI) | 56.39 |
| Average Volume (20 Days) | 49,700 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ulisse Biomed had revenue of EUR 767,929 and -5.94 million in losses. Loss per share was -0.24.
| Revenue | 767,929 |
| Gross Profit | -1.08M |
| Operating Income | -6.19M |
| Pretax Income | -5.94M |
| Net Income | -5.94M |
| EBITDA | -3.27M |
| EBIT | -6.19M |
| Loss Per Share | -0.24 |
Balance Sheet
The company has 1.50 million in cash and 333,889 in debt, giving a net cash position of 1.17 million or 0.05 per share.
| Cash & Cash Equivalents | 1.50M |
| Total Debt | 333,889 |
| Net Cash | 1.17M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 23.67M |
| Book Value Per Share | 0.97 |
| Working Capital | 3.09M |
Cash Flow
In the last 12 months, operating cash flow was -3.56 million and capital expenditures -2,906, giving a free cash flow of -3.56 million.
| Operating Cash Flow | -3.56M |
| Capital Expenditures | -2,906 |
| Free Cash Flow | -3.56M |
| FCF Per Share | -0.15 |
Margins
| Gross Margin | -140.15% |
| Operating Margin | -806.30% |
| Pretax Margin | -773.49% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ulisse Biomed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -29.09% |
| FCF Yield | -17.44% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ulisse Biomed has an Altman Z-Score of 2.77. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.77 |
| Piotroski F-Score | n/a |